Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
39 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Enterocolitis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Enterocolitis - Pipeline Review, H2 2014', provides an overview of the Enterocolitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Enterocolitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterocolitis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Enterocolitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Enterocolitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Enterocolitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Enterocolitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Enterocolitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Enterocolitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Enterocolitis Overview 6 Therapeutics Development 7 Pipeline Products for Enterocolitis - Overview 7 Pipeline Products for Enterocolitis - Comparative Analysis 8 Enterocolitis - Therapeutics under Development by Companies 9 Enterocolitis - Therapeutics under Investigation by Universities/Institutes 10 Enterocolitis - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Enterocolitis - Products under Development by Companies 13 Enterocolitis - Products under Investigation by Universities/Institutes 14 Enterocolitis - Companies Involved in Therapeutics Development 15 Sigma-Tau Pharmaceuticals, Inc 15 AvidBiotics Corp. 16 Enterocolitis - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 23 Drug Profiles 25 STP-206 - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 C-34 - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Recombinant Proteins to Disrupt Bacterial Cell Membrane for Bacterial Infections - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Peptide for Enterocolitis and Infectious Diarrhea - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Recombinant Peptide to Activate Mucin 3 for Enterocolitis and Infectious Diarrhea - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Enterocolitis - Recent Pipeline Updates 31 Enterocolitis - Dormant Projects 32 Enterocolitis - Product Development Milestones 33 Featured News & Press Releases 33 Feb 04, 2014: Sigma-Tau Pharmaceuticals, Inc. Announces First Patient Dosed in Phase I/II Clinical Trial of STP206 for Prevention of Necrotizing Enterocolitis in Very Low Birth Weight Premature Infants 33 Apr 11, 2012: Prasco To Launch Generic Version Of Vancocin HCl Capsules 33 Apr 10, 2012: ViroPharma Provides Update On Status Of Citizen Petition Regarding Bioequivalence And Exclusivity For Vancocin Capsules 34 Dec 14, 2011: ViroPharma Announces Approval Of Modernized Labeling For Vancocin Capsules 35 Apr 07, 2009: Sigma-Tau Partners With Danisco Bioactive To Develop Drug Candidate For Prevention Of Necrotizing Enterocolitis 37 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 39 Disclaimer 39
List of Tables Number of Products under Development for Enterocolitis, H2 2014 7 Number of Products under Development for Enterocolitis - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Products under Investigation by Universities/Institutes, H2 2014 14 Enterocolitis - Pipeline by Sigma-Tau Pharmaceuticals, Inc, H2 2014 15 Enterocolitis - Pipeline by AvidBiotics Corp., H2 2014 16 Assessment by Monotherapy Products, H2 2014 17 Number of Products by Stage and Target, H2 2014 19 Number of Products by Stage and Mechanism of Action, H2 2014 21 Number of Products by Stage and Route of Administration, H2 2014 22 Number of Products by Stage and Molecule Type, H2 2014 24 Enterocolitis Therapeutics - Recent Pipeline Updates, H2 2014 31 Enterocolitis - Dormant Projects, H2 2014 32
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.